MedinCell S.A.

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceuti…

Biotechnology

FR, Jacou [HQ]

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Outstanding & Floating

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. It's perfect to get a quick briefing regarding the shareholder structure of MedinCell S.A.

MedinCell S.A. can't present any analysts estimates at the moment detail analysis.

Beneficial Owners Beta

Beneficial owners hold at least 10% of the stocks outstanding. Palmy retrieves this information from the most reliable, audited format which presents the data, the proxy statement.

Soon Available - Stay Tuned